Atavistik Bio Collaborates with Pfizer to Advance Precision Allosteric Therapeutics

European Commission Approves Amivantamab-Lazertinib Combination for First-Line Treatment of EGFR-Mutated NSCLC

Sangamo Therapeutics Regains Rights to Hemophilia A Gene Therapy Following Pfizer Exit

Innovent Biologics Collaborates with Roche to Advance DLL3 ADC Candidate IBI3009

CARsgen Therapeutics Announces Positive Phase II Results for Satricabtagene Autoleucel in Gastric Cancer

IDEAYA Biosciences and Hengrui Pharma Collaborate on Novel DLL3-Targeting ADC for Precision Oncology

Novartis Reports Positive Phase III STEER Study Results for OAV101 IT in SMA Type 2 Patients

Digital Pathology Biomarkers: Transforming Precision Oncology Diagnostics and Treatment

DATROWAY® Approved in Japan for HR Positive, HER2 Negative Breast Cancer

FDA Approves Injectable Form of Opdivo, Offering Greater Convenience for Cancer Patients

Reliance Acquires Oncology Platform Karkinos for ₹375 Crore

FDA Approves TEVIMBRA® for First-Line Treatment of PD-L1-Positive Gastric and Gastroesophageal Junction Cancers

CSIR's 2024 Healthcare Breakthroughs: Advancing Cancer Detection, Genetic Disorders, and Neurodegenerative Disease Research

Dr. Sandip Shah Appointed Chairman of NABL: A Visionary Leader in Indian Healthcare

Global and Indian Genetic Testing Market Trends in 2025

Home
/
update
/
details

Mirxes and Universiti Kebangsaan Malaysia Collaborate on Colorectal Cancer Detection Test

NextEdge Admin

19 Jul 2024

2 min 15 sec

Universiti Kebangsaan Malaysia's Medical Molecular Biology Institute (UMBI) has signed a Memorandum of Understanding (MoU) with Singapore-based Mirxes Pte Ltd to develop a blood-based early detection test for colorectal cancer in Malaysia.

In their joint statement, UKM and Mirxes emphasized the drawbacks of the current screening method, the immunochemical Faecal Occult Blood Test (iFOBT), which has low sensitivity for early-stage colorectal cancer and is inconvenient for patients. The new partnership intends to leverage UMBI's expertise in cancer research and Mirxes' proprietary microRNA technology to develop a more accurate, convenient, and accessible screening solution.

The collaboration will utilize archived biospecimens from UMBI and the Malaysian Cohort Biobank, the largest biobank in Southeast Asia, to identify biomarkers for an early detection test that is both precise and sensitive. The MoU also includes staff exchange and training programs for knowledge transfer between UKM and Mirxes, and the establishment of a joint laboratory dedicated to translational research and clinical testing.

Both parties have expressed their intention to expand their research focus beyond colorectal cancer. This partnership could lead to the development and commercialization of a variety of blood-based cancer early detection tests made in Malaysia.

Mirxes Cofounder and CEO Zhou Lihan emphasized Malaysia's significance as a key market, expressing the company's commitment to co-develop and make accessible their range of blood-based cancer early detection tests, beginning with colorectal cancer.